



**Neuron Experts, Motac Neuroscience, and Cynbiose introduce INSPIRE:  
Integrated Neuroscience Solutions for Preclinical REsearch.**

Neuron Experts, Motac Neuroscience, and Cynbiose are proud to officially unveil the name of their strategic partnership: INSPIRE.

In a world where the population is getting older, the burden of neurodegenerative diseases is growing rapidly and is affecting families and healthcare systems worldwide. According to a recent study, Parkinson's disease is projected to affect over 25.2 million people by 2050, while Alzheimer's disease cases are expected to reach 80 million by 2040 globally ([BMJ, 2025](#)).

INSPIRE embodies a new stage reflecting the shared ambition of three leading preclinical CROs to accelerate research in neurology by offering a translational joint expertise to support CNS drug development. Our partnership is an end-to-end solution combining the *in vitro* expertise for the neurodegenerative model of Neuron Experts, the *in vivo* neurological disease models of Motac Neuroscience, and Cynbiose's expertise in efficacy and toxicity studies in non-human primate models.

Motac Neuroscience brings to INSPIRE its long-standing expertise in translational neuroscience, built on advanced *in vivo* models of Parkinson's and Alzheimer's disease. By combining behavioural, histological, and neurochemical endpoints within these models, Motac contributes to refining and reinforcing the consortium's preclinical evaluation capabilities.

Working hand in hand with Motac, Neuron Experts' advanced *in vitro* systems reveal the earliest cellular mechanisms of neurodegeneration and provide a mechanistic framework to Motac's *in vivo* models. This offer is completed by Cynbiose's ability to run IND-enabling toxicology and CNS-targeting biodistribution studies in NHP, leveraging state-of-the-art neurosurgical and imaging capabilities.

This integrated approach is central to INSPIRE's ambition to deliver more predictive and clinically relevant preclinical data.

*"Our added value is based on our scientific complementarity, enabling us to offer a coherent preclinical development program from in vitro to in vivo."  
Rémy Steinschneider, CEO of Neuron Experts*

*"At Motac, we have always believed that advancing translational neuroscience requires joining forces across specialisations. INSPiRE gives this principle a concrete form – bringing together complementary capabilities that will significantly enhance the reliability and translational relevance of CNS drug discovery."  
Erwan Bezard, CEO and CSO of Motac Neuroscience*

*"This new milestone in our partnership reaffirms our shared commitment to accelerating innovation in CNS research. Through INSPiRE, we provide our clients with an integrated and concrete solution, leveraging the combined experience and expertise of our companies, to support drug validation and transition to clinical trials."  
Hugues Contamin, CEO of Cynbiose*

Join Rémy Steinschneider and Erwan Bezard at the Society for Neuroscience Annual Meeting – Neuroscience 2025, taking place in San Diego from November 15-19.

They will be pleased to discuss how the INSPiRE consortium can advance your CNS drug development through tailored preclinical solutions.

Visit us at Booth 430 to start a conversation.

**Media Contact:**

For press inquiries or to schedule a meeting at SfN, please contact us.

Neuron Experts:

Rémy Steinschneider, *CEO*

[remy.steinschneider@neuronexperts.com](mailto:remy.steinschneider@neuronexperts.com)

Motac Neuroscience:

Leslie Largeais, *Community Manager*

[leslie.largeais@motac.com](mailto:leslie.largeais@motac.com)

Cynbiose:

Joachim Confais, *CSO*

[joachim.confais@cynbiose.com](mailto:joachim.confais@cynbiose.com)